All In Biotech

Drug Trial Radar · NCT02714010

EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLC

Whole Brain Radiotherapy Concurrent With EGFR-TKI Versus EGFR-TKI Alone in the Treatment of Non-small Cell Lung Cancer Patients With Brain Metastasis

Last checked: Nov 19, 2026Latest source record: Oct 27, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 601 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

601

Planned (sponsor's estimate)

Start

Aug 2015

Primary completion

Dec 2021

Study completion Dec 2022

Sponsor

Lead sponsor
Sun Yat-sen UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 21, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center phase III randomized controlled study, designing to access whether the efficacy of EGFR-TKI alone on patients with brain metastasis from non-small cell lung cancer (NSCLC) harboring EGFR mutant type is not inferior to EGFR-TKI concurrent with whole brain radiotherapy (WBRT), the primary end point is intracranial PFS (iPFS), while secondary outcomes included overall survival (OS), objective response rate (ORR), evaluation of cognitive function, quality of life (QoL) and adverse events.

Conditions

  • Non-Small Cell Lung Cancer

Interventions

  • EGFR-TKIDrug

    Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid

  • whole brain radiotherapyRadiation

    30Gy/10F

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. intracranial PFS (iPFS)Time frame: up to 41 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University of cancer center

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.